ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Baqsimi (nasal glucagon) by Year
Baqsimi (nasal glucagon) — Outside U.S. revenue ($M) [legacy] ($M)
Eli Lilly Baqsimi (nasal glucagon): $26.7M in FY2024, down 16.3% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2024
26.7
Period ended Dec 31, 2024
Change on a year earlier
-16.3%
31.9 in FY2023
History
4 years
Since FY2021
Sources
2
Documents cited below
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-19) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Baqsimi (nasal glucagon) — Outside U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 26.7 | -16.3% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 31.9 | +10.4% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 28.9 | +72.0% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 16.8 | – | Form 10-K (filed 2024-02-21) ↗ |
Cite this data
StockData. (2026). Eli Lilly Baqsimi (nasal glucagon) ($M), annual FY2021–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-baqsimi-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.